Drug Profile
Botulinum toxin A topical - AbbVie
Alternative Names: ANT 1207Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Anterios
- Developer Allergan
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acne vulgaris; Facial wrinkles; Hyperhidrosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 07 Feb 2018 Discontinued - Phase-II for Hyperhidrosis, Facial wrinkles and Acne vulgaris in USA (Topical) (not listed on Allergan pipeline, February 2018)
- 01 Feb 2016 Anterios completes a phase II trial in Hyperhidrosis in USA (NCT02479139)